SCHEMBL17075414

SCHEMBL17075414

Cc1ccc(-c2onc3ccc(-c4ccnn4-c4ccc(F)cc4)cc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
KDM4E B2RXH2 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALDH1A1 P00352 4/20 0.48
RAB9A P51151 4/20 0.47
POLB P06746 3/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
PTK2B Q14289 1/20 0.47
MAPK14 Q16539 1/20 0.47
LMNA P02545 2/20 0.46
PABPC1 P11940 1/20 0.46
IP6K1 Q92551 2/20 0.46
IP6K3 Q96PC2 2/20 0.46
IP6K2 Q9UHH9 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NR3C2 P08235 2/20 0.41
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17075426 1.00 MEN1 (0.48) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15556017 0.94 MEN1 (0.52) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL17075423 0.94 ALDH1A1 (0.52) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15560333 0.89 SMN1; SMN2 (0.48) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15557300 0.89 MEN1 (0.43) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15556015 0.89 PIM1 (0.47) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL17075429 0.89 PIM1 (0.47) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15556689 0.89 ALDH1A1 (0.48) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15557174 0.88 MEN1 (0.53) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL15560352 0.88 PIM1 (0.47) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440962-B2 Benzisoxazoles HOFFMANN-LA ROCHE INC. (US) 2016-09-13 US claimed
EP-2877466-B1 BENZISOXAZOLE MODULATORS OF NEUROGENESIS HOFFMANN LA ROCHE (CH) 2016-07-06 EP claimed
US-20150259334-A1 BENZISOXAZOLES HOFFMANN-LA ROCHE INC. (US) 2015-09-17 US claimed
US-9440962-B2 Benzisoxazoles HOFFMANN-LA ROCHE INC. (US) 2016-09-13 US disclosed
US-9440962-B2 Benzisoxazoles HOFFMANN-LA ROCHE INC. (US) 2016-09-13 US disclosed
US-9440962-B2 Benzisoxazoles HOFFMANN-LA ROCHE INC. (US) 2016-09-13 US disclosed
EP-2877466-B1 BENZISOXAZOLE MODULATORS OF NEUROGENESIS HOFFMANN LA ROCHE (CH) 2016-07-06 EP disclosed
EP-2877466-B1 BENZISOXAZOLE MODULATORS OF NEUROGENESIS HOFFMANN LA ROCHE (CH) 2016-07-06 EP disclosed
US-20150259334-A1 BENZISOXAZOLES HOFFMANN-LA ROCHE INC. (US) 2015-09-17 US disclosed
US-20150259334-A1 BENZISOXAZOLES HOFFMANN-LA ROCHE INC. (US) 2015-09-17 US disclosed
US-20150259334-A1 BENZISOXAZOLES HOFFMANN-LA ROCHE INC. (US) 2015-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259334-A1 BENZISOXAZOLES CDR2, CHRNA5, CHRNA3 MEN1 1009/4885KMT2A 3915/4885KDM4E 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.